Gathering the record
Relay is organizing the evidence and source boundaries.
Mitochondrial-derived signaling peptide
MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA and studied as a signal involved in cellular energy stress. Human studies have mostly measured the body's own MOTS-c rather than administering it. A Phase 2a insulin-sensitivity trial is enrolling, but it has no results yet.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
MOTS-c is a small peptide encoded within mitochondrial DNA. Mitochondria are the cell structures that help turn nutrients into usable energy.
Laboratory work links MOTS-c with how cells respond to energy stress, while animal studies explore metabolism, glucose handling, and physical performance. Researchers also measure naturally produced MOTS-c to ask whether its level tracks aging, exercise, or metabolic disease.
Original studies reported metabolic effects in mice. Human studies have mainly measured naturally occurring MOTS-c rather than giving the peptide, so those associations do not demonstrate a treatment effect.
No completed controlled human efficacy record for administered native MOTS-c was located. Human exposure, absorption, effective concentration, safety, clinical benefit, and reconstitution all remain unresolved.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
The original administration research located for this pass used mouse models. FDA's 2026 review identified no publicly available clinical study or human exposure record for administered MOTS-c-related substances.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Human administration research is limited to an enrolling Phase 2a trial with no posted results; the completed human record measures endogenous MOTS-c rather than giving the peptide.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Metabolic and exercise findings are primarily mouse, cell, or observational biomarker evidence, and native MOTS-c has no completed human efficacy dataset.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Animal exposure does not establish a human amount, route, efficacy result, or safety profile. No verified human reconstitution, administration, pharmacokinetic, or stability evidence was located. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Human studies show that endogenous MOTS-c changes with exercise and is associated with some metabolic and vascular phenotypes. No completed controlled human efficacy results for administered native MOTS-c were publicly available at the cutoff.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Whether administered native MOTS-c improves insulin sensitivity, body composition, physical performance, or meaningful health outcomes in people, and whether repeated exposure is safe.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
The peptide is encoded within the mitochondrial 12S rRNA region. Laboratory work connects it with AMPK-related signaling, altered folate-purine metabolism, and stress-responsive nuclear gene expression.
Human papers largely measure naturally occurring MOTS-c. The first sizable native-MOTS-c metabolic trial is enrolling and has no posted results.
Researchers measured a large post-exercise increase in skeletal-muscle MOTS-c and a smaller temporary rise in blood. The participants exercised; they did not receive the peptide.
Studies have reported different endogenous MOTS-c patterns in diabetes, obesity, and coronary endothelial dysfunction. Those patterns may be causes, consequences, or compensatory responses.
The study plans to enroll 120 adults with prediabetes and overweight or obesity and test insulin sensitivity after 12 weeks.
CB4211 is described as an optimized analog derived from MOTS-c. A related molecule may inform development, but it can differ in exposure, potency, safety, and biological effects.
Experimental MOTS-c improved glucose handling and diet-related metabolic measures in mice, and later mouse work reported performance and healthspan signals.
The advisory committee voted 7–5, with two abstentions, to recommend possible 503A Bulks List inclusion. The vote was non-binding, final FDA action remained pending, and compounding status is separate from drug approval.
The 2026 Prohibited List names MOTS-c in S4.4 among AMPK activators and metabolic modulators prohibited at all times.
Mechanisms
MOTS-c is a mitochondrial-derived microprotein encoded within the 12S rRNA region. Preclinical work links it to folate-purine metabolism, AICAR accumulation, AMPK-related signaling, skeletal-muscle glucose handling, and stress-induced nuclear gene regulation. A validated cell-surface receptor has not been established. Human evidence is dominated by small endogenous-biomarker and observational studies; controlled efficacy and repeated-exposure safety for administered native MOTS-c remain unresolved.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Meta-analysis of six case-control studies and one cross-sectional study examining circulating mitochondrial-derived peptides and metabolic measures
People with and without diabetes or obesity across 11 comparison groups
Pooled results associated lower circulating MOTS-c with diabetes but higher levels with obesity. The directions differed by metabolic condition.
Study administration: No MOTS-c administration; studies measured endogenous circulating levels
Limitations: Small heterogeneous observational studies cannot determine whether MOTS-c causes, compensates for, or merely accompanies metabolic differences. They do not test MOTS-c treatment.
Acute exercise study measuring the body's endogenous MOTS-c before, during, and after stationary cycling
Healthy, sedentary young men
Skeletal-muscle MOTS-c increased about 11.9-fold after exercise, while circulating levels rose more modestly during and shortly after exercise before returning toward baseline.
Study administration: Stationary-bicycle exercise; participants were not administered MOTS-c
Limitations: This was a 10-person biomarker study in young men. It shows an endogenous response to exercise, not that injected MOTS-c improves exercise performance or health.
Cell-based metabolic-stress experiments examining MOTS-c localization and gene-expression responses
Cultured human cells
MOTS-c moved into the nucleus during metabolic stress and influenced adaptive nuclear gene expression in an AMPK-dependent manner.
Study administration: Metabolic stress with experimental MOTS-c pathway manipulation
Limitations: A cellular mechanism does not establish a validated human molecular target, clinical effect, or safe treatment strategy.
Cross-sectional measurement of circulating endogenous MOTS-c in people undergoing invasive coronary endothelial-function testing
Adults evaluated for coronary endothelial dysfunction
Lower circulating MOTS-c was associated with coronary endothelial dysfunction.
Study administration: No MOTS-c administration
Limitations: The study was observational and cannot show that low MOTS-c caused dysfunction or that administering MOTS-c would improve cardiovascular outcomes.
Cell experiments and mouse metabolic studies, including high-fat-diet models
Cultured cells and mice
The study identified MOTS-c as a 16-amino-acid mitochondrial-derived peptide and reported improved metabolic measures in experimental models, including protection against diet-induced obesity and insulin resistance in mice.
Study administration: Experimental MOTS-c exposure in cells and mice
Limitations: Cell and mouse results establish biological plausibility, not efficacy, dose, or safety in humans.
Randomized, quadruple-blind, placebo-controlled, parallel-group trial with 1:1 allocation and standardized lifestyle counseling
Adults aged 18–65 with prediabetes and BMI 27–40 kg/m²
No results are posted. This trial is designed to test whether native investigational MOTS-c improves insulin sensitivity in people rather than only in animal or cell models.
Study administration: Subcutaneous investigational MOTS-c or matching placebo; the public registration does not disclose the MOTS-c dose
Limitations: An enrolling registration does not demonstrate benefit or safety. Enrollment, completion, results, peer review, and replication remain pending.
Safety snapshot
No source-qualified adverse-event pattern is represented in the current record.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryNot FDA approved. Phase 2a MOTS-MET is enrolling without results. PCAC recommended possible 503A Bulks List inclusion on July 23, 2026; final FDA action remained pending at the evidence cutoff. WADA S4.4 prohibited. Whether administered native MOTS-c improves insulin sensitivity, body composition, physical performance, or meaningful health outcomes in people, and whether repeated exposure is safe.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-07-23
2026-07-23
2026-04-01 · NCT07505745
2026-01-01
2024-08-19 · PMID 39160573 · DOI 10.1186/s13098-024-01451-y
2021-01-20 · PMID 33473109 · DOI 10.1038/s41467-020-20790-0
2019-06-26 · NCT03998514
2018-07-10 · PMID 29983246 · DOI 10.1016/j.cmet.2018.06.008
2018-02-01 · PMID 29242099 · DOI 10.1016/j.ijcard.2017.11.077
2015-03-03 · PMID 25738459 · DOI 10.1016/j.cmet.2015.02.009